MedTrace Logo

Efficacy and Safety of HMM1-022 in Temporary Correction of Crow's Feet

NCT06428253 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 171

Last updated 2025-12-11

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy and safety of HMM1-022 with Rejuran to improve Crow's feet

Conditions

  • Crow's Feet

Interventions

DEVICE

HMM1-022

intradermal injection

Sponsors & Collaborators

  • Humedix Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Beom Joon Kim, M.D. · Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-14
Primary Completion
2025-11-27
Completion
2025-11-27

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06428253 on ClinicalTrials.gov